News Releases

POWERWAND Midline IV Catheter Achieves 23,000 Catheter Days with Zero Bloodstream Infections

SAN DIEGO, Oct. 24, 2017 /PRNewswire/ -- Access Scientific announced today that the POWERWAND™ midline catheter now has over 23,000 catheter days of scientific data without a single catheter-related bloodstream infection (CRBSI).  This follows new data presented at the prestigious Association for Vascular Access national conference, which took place in Phoenix, AZ in late September.

Data collected at Methodist Hospitals in Indiana,  representing 2,688 patient days of POWERWAND use, indicated the use of POWERWAND lead to a 35% reduction in the number of peripherally inserted central catheters (PICCs) placed.  Zero bloodstream infections were reported during the 12-month study period and 79% of patients utilized POWERWAND through their completion of therapy.

Methodist Hospitals' data, coupled with five peer-reviewed, published studies and seven scientific posters demonstrate POWERWAND's consistently superior performance.  In addition to the zero CRBSI achievement, the accumulated studies & posters prove POWERWAND's superior blood drawability and lowest total complication rate and highest completion of therapy rate of any midline ever studied.

POWERWAND is made of a unique catheter material (ChronoFlex C®) that, when coupled with Access Scientific's proprietary manufacturing processes, produces a catheter capable of outperforming the competition. 

"The consistently superior clinical performance of the POWERWAND is extraordinary," remarked Steve Bierman, Access Scientific's Founder and Chief Medical Officer. "POWERWAND's proprietary catheter material and manufacturing processes are unparalleled.  POWERWAND is the evidence-based midline of choice."

About Access Scientific, LLC

Access Scientific, LLC, based in San Diego, CA, is an evidence-based, infection prevention company offering innovative vascular access devices designed to reduce the need for and risk of vascular device-related complications, including bloodstream infections. See www.accessscientific.com for full product offering and clinical studies.

Contact:  Liz Dowling, (415) 388-2794
Dowling & Dennis Public Relations
Email: Liz@DowlingDennis.net 

 

SOURCE Access Scientific, LLC